Koefoed
Anders Koefoed, Kobenhavn N DK
Patent application number | Description | Published |
---|---|---|
20130208910 | HEADSET WITH PIVOTAL PARTS - A headset includes a battery and transmission part shaped to rest behind and above the ear lobe of a user and a speaker and microphone part arranged to extend downwards in front of the ear canal. The two parts are interlinked to pivot with respect to each other and the battery and transmission part accommodates a battery as well as signal processing and transmission electronics, and the speaker and microphone part accommodates a speaker element and a microphone boom arm and further, the two parts have mating surfaces such that a pivotal motion between the two, when the device is not at the ear, will bring a surface of the first part and a surface of the second part together. A magnet is inserted in the one part and a sensor for sensing the magnetic field from the magnet is comprised in the other part, such that movement between the two parts may be registered and used to control the function of the headset or for giving audible indication signals to the user. | 08-15-2013 |
20130208940 | HEADSET WITH PIVOTAL PARTS - The invention concerns a communication device for placement at the ear of a user. A battery and transmission part is shaped to rest behind and above the ear lobe of a user and a speaker and microphone part is arranged to extend downwards in front of the ear canal. The two parts are interlinked to pivot, at least in the sagittal plane, with respect to each other and the battery and transmission part accommodates a battery as well as signal processing and transmission electronics, and the speaker and microphone part accommodates a speaker element and a microphone boom arm and further, the two parts have mating surfaces such that a pivotal motion between the two, when the device is not at the ear, will bring a surface of the first part and a surface of the second part together. Further the link between the two parts comprises a hollow ball joint connection allowing leads to pass through the ball joint. Also a magnet is inserted in the one part and a sensor for sensing the magnetic field from the magnet is comprised in the other part, such that the movement between the two parts may be registered and used to control the function of the device or for giving audible indication signals to the user. | 08-15-2013 |
Brian Koefoed, Glostrup DK
Patent application number | Description | Published |
---|---|---|
20130210496 | PERSONAL CONFERENCING DEVICE - A personal conferencing device ( | 08-15-2013 |
Klaus Koefoed, Kobenhavn S DK
Patent application number | Description | Published |
---|---|---|
20110250203 | ANTI-CD5 ANTIBODIES - The present invention relates to the field of compositions comprising anti-CD5 antibodies. In particular, the present invention concerns an antibody composition comprising at least two anti-CD5 antibodies capable of binding distinct CD5 epitopes. The invention further concerns bi-specific molecules having the binding specificities of said antibody compositions. The invention also relates topharmaceutical compositions, use of antibody compositions and methods for manufacturing antibody compositions. The invention further relates to cell banks and a method for killing cells. | 10-13-2011 |
20130287684 | ANTI-HER3 ANTIBODIES AND COMPOSITIONS - The present invention relates to novel therapeutic recombinant antibodies directed against HER3 (ErbB3), as well as compositions comprising mixtures of at least two of said recombinant anti-HER3 antibodies, and use of the antibodies and antibody compositions for treatment of cancer. | 10-31-2013 |
20150086478 | HUMANIZED PAN-HER ANTIBODY COMPOSITIONS - The invention relates to humanized recombinant antibodies targeting the EGFR family receptors EGFR, HER2 and HER3, compositions comprising at least one humanized anti-EGFR antibody, at least one humanized anti-HER2 antibody and at least one humanized anti-HER3 antibody, and use of the antibody compositions for treatment of cancer. The invention also relates to the use of antibodies targeting multiple EGFR-family receptors to treat cancer (e.g., pancreatic cancer) and cancer that has acquired resistance to previous therapies. | 03-26-2015 |
Klaus Koefoed, Copenhagen S DK
Patent application number | Description | Published |
---|---|---|
20090004192 | Recombinant anti-epidermal growth factor receptor antibody compositions - The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody. | 01-01-2009 |
20100069262 | Method for Cloning Avian-Derived Antibodies - The invention relates to a procedure for linking cognate pairs of VH and VL encoding sequences from a population of avian cells enriched in particular surface antigen markers. The linking procedure involves a multiplex molecular amplification procedure capable of linking nucleotide sequences of interest in connection with the amplification (multiplex PCR). The method is particularly advantageous for the generation of cognate pair libraries as well as combinatorial libraries of antibody variable region encoding sequences from chickens or other birds. The invention also provides methods for generation of chimeric human/avian antibodies and expression libraries generated by such methods. | 03-18-2010 |
20110129855 | Recombinant Anti-Epidermal Growth Factor Receptor Antibody Compositions - The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody. | 06-02-2011 |
20110135636 | Recombinant Anti-Epidermal Growth Factor Receptor Antibody Compositions - The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides compositions or mixtures of antibodies capable of binding human EGFR. Antibody compositions with 3 or more antibodies shown synergy in reduction of proliferation of representative cancer cell lines. Advantageous results have also been obtained with a composition comprising two different chimeric anti-hEGFR antibodies which show a new mechanism of action based on rapid and efficient receptor internalisation, induction of terminal differentiation and subsequent tumour eradication in an animal model. The antibodies of the invention can be manufactured in one bioreactor as a polyclonal antibody. | 06-09-2011 |
Klaus Koefoed, Copenhagen DK
Patent application number | Description | Published |
---|---|---|
20100040606 | Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections - Disclosed are novel polyclonal antibodies, which target respiratory syncyticilal virus (RSV), and novel high affinity antibody molecules reactive with RSV. The polyclonal antibodies may comprise antibody molecules which are reactive with both RSV protein F and RSV protein G, and preferably the polyclonal antibodies target a variety of epitopes on these proteins. The single antibody molecules of the invention are shown to exhibit affinities which provide for dissociation constants as low as in the picomolar range. Also disclosed are methods of producing the antibodies of the invention as well as methods of their use in treatment for RSV infection. | 02-18-2010 |
Klaus Koefoed, Lyngby DK
Patent application number | Description | Published |
---|---|---|
20140356375 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 12-04-2014 |
20140356376 | ANTI-WALL TEICHOIC ANTIBODIES AND CONJUGATES - The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same. | 12-04-2014 |
Michael Schølarth Koefoed, Vejen DK
Patent application number | Description | Published |
---|---|---|
20120007269 | METHOD OF MANUFACTURING PRE-BENT WIND TURBINE BLADES - In a method of manufacturing a blade shell half of a pre-bent wind turbine blade by means of vacuum-assisted resin transfer moulding (VARTM), a fibre lay-up ( | 01-12-2012 |
Peter Koefoed, Horsholm DK
Patent application number | Description | Published |
---|---|---|
20100047262 | NOVEL METHOD FOR DOWN-REGULATION OF AMYLOID - Disclosed are novel methods and compositions for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous APP or Aβ, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations. | 02-25-2010 |